3.5. Intraoral Administration (Gavage) of LR-IL-22 Induced PD-L1 Protein Release in Ovarian Cancer Cells, Mobilized CD8+ T Cells in the WAI Mice, and Improved Overall Survival When Combined with a PD-L1 Inhibitor. This evidence concerns the gene CD8A and ovarian carcinoma.